Here, we nominate CAMKV as an immunotherapeutic target for MYCN amplified neuroblastoma, and suggest pursuing the identification of specific human scFv binders to this protein for the creation of antibody-drug conjugate therapeutics that should not cross the blood-brain barrier. The gene discussed is MYCN; the disease is neuroblastoma.